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as lower amputation rates (BLCC: -27.6% p= 0.04, HFDS: -22.2% p= 0.19) during the 
18-month follow-up period. While BLCC and HFDS patients did have higher costs 
for outpatient services (BLCC: +$7,100 p< 0.01, HFDS: +$11,947 p< 0.01), overall, these 
patients had lower average per-patient healthcare costs during the 18-month follow-
up period compared with their respective matched CC counterparts (BLCC: -$5,253 
p= 0.49, HFDS: -$6,991 p= 0.84). ConClusions: These findings suggest that use of 
BLCC and HFDS for treatment of DFU may lower overall medical costs through 
reduced utilization of costly healthcare services.
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objeCtives: In the recent Pathway CH-1 study, on-demand stimulation of the sphe-
nopalatine ganglion (SPG) by means of an implantable neurostimulation system was 
proven to be a safe and effective therapy for the treatment of chronic cluster head-
ache. Our objective was to assess the cost-effectiveness of SPG stimulation in the 
German healthcare system when compared to medical management. Methods: 
Clinical data from the Pathway CH-1 study were used as input for a model-based 
projection of the cost-effectiveness of SPG stimulation through 5 years. Medical 
management as the comparator treatment was modeled on the basis of clinical 
events observed during the baseline period of CH-1. The costs of treatment were 
derived from a previously published cluster headache costing study and2014 medi-
cation, neurostimulator, and procedure costs. We computed the 5-year incremental 
cost-effectiveness ratio (ICER) in euros per quality-adjusted life year (QALY), with 
costs and effects discounted at 3% per year. Results: SPG stimulation was pro-
jected to add 0.325 QALYs over the study period, while adding € 681 in cost, resulting 
in a 5-year ICER of € 2,097 per QALY gained. Longer follow-up periods, higher baseline 
attack frequency, and higher utilization of attack-aborting medications led to overall 
cost savings. SPG stimulation was found either cost-effective or cost-saving across 
all scenarios investigated in sensitivity analyses. ConClusions: Our model-based 
analysis suggests that SPG stimulation for the treatment of chronic cluster head-
ache, under the assumption of sustained therapy effectiveness, leads to meaningful 
gains in health-related quality of life and is a cost-effective treatment strategy in 
the German healthcare system.
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objeCtives: The objective was to study the economic and humanistic outcomes 
among acute coronary syndrome patients receiving percutaneous coronary inter-
vention (PCI) in a tertiary care setup in South India. Methods: Total 240 acute 
coronary syndrome patients visiting to tertiary care multispecialty hospital in south 
India were included in to the study from 2011 to 2013. Prior ethical approval was 
taken and patients were included after signing the consent form. All the patients 
included were receiving PCI first time. Socio-demographic, clinical diagnostic and 
risk factor data was collected using a pilot tested data collection sheet. EQ5D was 
used to collect the humanistic data on discharge, 1 month, 3 month, 6 month follow 
up. The cost incurred in the intervention and other direct costs were taken from the 
bill paid by the patient at discharge. SPSS 15.0 was used to analyse the collected data 
and demographic results were represented with descriptive statistics and Mann-
Whitney test was carried to compare the costs among both the groups. Repeated 
measures ANOVA was done to check the difference in VAS score in baseline and 
follow-up cases. Results: 80 percent of the patients were males and their mean 
age was 57.65 ±10.103 with 70 of them coming from rural background. Average 
monthly income of the patients receiving BMS and DES was found to be 10212.5 ± 
8750 and 12859.28 ± 7673.277 respectively. Almost half of the patients were having 
hypertension as a major co-morbid condition. Smoking, sedentary lifestyle and 
alcohol consumption ware predominant risk factors. Baseline EQ5D VAS scores were 
0.5054 ± 0.1848 and 0.4715 ± 0.1615 among patients receiving BMS and DES. There 
was a significant difference (p< 0.001) in the cost among the patients receiving both 
BMS and DES. ConClusions: There is a significant difference in the cost incurred 
and health related quality of life achieved among both groups due to disparity in 
economic status.
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objeCtives: To develop a system dynamics model with a stochastic component to 
analyse the cost-effectiveness of bacterial whole-genome sequencing (WGS) versus 
current typing methods to detect and monitor outbreaks of methicillin-resistant 
Staphylococcus aureus (MRSA) in the UK National Health Service (NHS). Methods: 
The model, developed in R, simulated a low-risk ward and a high-risk ward (e.g. an 
intensive care unit). Patients were assumed to move between three states: suscep-
tible, colonised, or infected (symptomatic). Healthcare workers were either uncon-
taminated or MRSA-colonised. Clinical inputs were identified from peer-reviewed 
primary research papers, systematic reviews, published models, data published 
by the NHS and from clinical experts. Relevant costs were identified from the 
Department of Health guidelines on MRSA infection management, and other pub-
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objeCtives: Estimate the economic impact derived from the use of antibiotic-
impregnated catheters vs. traditional, non-antibiotic-impregnated catheters for 
the treatment of hydrocephalus in pediatric patients with external shunts from 
a Mexican public hospital perspective (IMSS). Methods: An Excel-based deci-
sion tree was used to estimate the economic consequences of using an antibiotic-
impregnated catheter (treatment group) vs. a catheter without antibiotic (control 
group) for target population. Given procedure volume variability in comparable 
hospitals, base-case scenario assumed 100 pediatric patients with hydrocepha-
lus and only one potential infection after first catheter placement; the antibiotic-
impregnated device was assumed as second-line treatment for both groups. 
Infection rates after catheter placement for considered alternatives were taken 
from published international meta-analyses (2.4% vs. 8.7% for treatment and control 
groups, respectively). Unitary costs were provided by internal resources (antibiotic-
impregnated device) and by public bid results for base-case hospital (traditional 
catheter). Considered time horizon was < 1 year, thus no annual discount rate for 
costs was necessary. Inflation-adjusted DRGs from IMSS´s high specialty hospitals 
were used as hospitalization (catheter placement) and catheter replacement costs. 
Results are shown in 2015-adjusted USD. Due to low reinfection rates documented 
in literature, posterior infections and mortality were not considered. Results: 
The total cost of the catheter with antibiotic strategy resulted in $1,610,600, while 
the non-antibiotic catheter strategy in $1,542,200, resulting in additional $684 per 
patient treated with the antibiotic-impregnated device and $11,400 per avoided 
infection. ConClusions: The use of antibiotic-impregnated catheters appears to 
be a cost-effective alternative to treat hydrocephalus in pediatric patients in the 
Mexican setting. Local high-specialty hospitals should consider the adoption of this 
alternative as it yields less infections in target population.
PMD30
Cost-utility of DeeP brain stiMulation for the treatMent of 
aDvanCeD Parkinson’s Disease in the uniteD states
Pietzsch J.B.1, Garner A.M.1, Marks W.J.2
1Wing Tech Inc., Menlo Park, CA, USA, 2University of California San Francisco, San Francisco, CA, 
USA
objeCtives: Deep brain stimulation (DBS), which uses an implantable device 
to modulate brain activity, has been shown to be clinically superior to medical 
therapy for treating advanced Parkinson’s disease. Our objective was to study the 
cost-utility of DBS in conjunction with medical therapy compared to best medical 
therapy (BMT) alone, using the latest clinical and cost data for the U.S. healthcare 
system. Methods: We used a decision-analytic state-transition (Markov) model 
to project Parkinson’s disease progression and associated costs for the two treat-
ment strategies. We estimated the discounted incremental cost-effectiveness ratio 
(ICER) in U.S. dollars per quality-adjusted life-year (QALY) from the Medicare payer 
perspective, considering a 10-year horizon. We evaluated the robustness of our 
projections through extensive deterministic sensitivity analyses. Results: Over 10 
years, DBS treatment led to discounted total costs of $129,345 compared to $91,026 
for BMT and added 1.69 QALYs more than BMT, resulting in an ICER of $22,713 per 
QALY. This ICER was relatively insensitive to variations in input parameters, with 
neurostimulator replacement timepoint, costs related to DBS implantation, and 
costs related to the treatment of disease-related falls having the greatest effects 
on the ratio. Across all investigated scenarios, including a 5-year horizon, ICERs 
remained under $50,000 per QALY. Longer follow-up periods and younger treatment 
age were associated with greater cost-effectiveness. ConClusions: Our findings 
suggest that DBS is a cost-effective treatment strategy in the U.S. healthcare sys-
tem across a wide range of assumptions. DBS yields substantial improvements in 
health-related quality of life at a value profile that compares favorably to other 
well-accepted therapies.
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objeCtives: To compare the real-world medical services utilization and associ-
ated costs of Medicare patients with diabetic foot ulcers (DFU) treated with either 
of the following two types of skin substitutes: bilayered living cellular construct 
(BLCC) or human fibroblast-derived dermal substitute (HFDS) with those receiving 
conventional care (CC). Methods: DFU patients were selected from Medicare de-
identified administrative claims using ICD-9-CM codes. The analysis followed an 
“intent-to-treat” design, with cohorts assigned based on use of (1) BLCC, (2) HFDS, or 
(3) CC (i.e., ≥ 1 claim for a DFU-related treatment procedure or podiatrist visit and no 
evidence of skin substitute use) for treatment of DFU in 2006-2012. Propensity score 
models were used to separately match BLCC and HFDS patients to CC patients with 
similar baseline demographics, wound severity, and physician experience measures. 
Medical resource use, lower-limb amputation rates, and total healthcare costs (2012 
USD; from payer perspective) during the 18 months following treatment initiation 
were compared separately among the two resulting matched samples. Results: 
Data for 502 matched BLCC-CC patient pairs and 222 matched HFDS-CC patient 
pairs were analyzed. Relative to matched CC patients, BLCC and HFDS patients 
had fewer days hospitalized (BLCC: -33.3% p< 0.01, HFDS: -42.4% p< 0.01) and fewer 
emergency department visits (BLCC: -32.3% p< 0.01, HFDS: -25.7% p< 0.01), as well 
